Navigation thread
Navigation thread
Vitiligo
Make a donation
Make a donation
Joint project with . This link opens in a new tab.

Vitiligo research at the Clínic

Reading time: 1 min

The Clínic Barcelona Hospital is currently participating in two phase III trials. These are in the study phase to determine whether the new treatments are safe and work correctly compared to standard treatments.
Specifically, these are two trials of two JAK inhibitor compounds (povorcitinib and ritlecitinib). JAKs are proteins that act as messengers, transmitting signals for the functioning of cells, especially in pro-inflammatory processes. When these signals get out of control, they can trigger diseases such as vitiligo. JAK inhibitors control this excess of signals and prevent pro-inflammatory processes, which are believed to be related to the appearance of vitiligo.

The aim of these treatments is to improve the repigmentation of the skin affected by the disease.

Read more Teaching and Training at Clinic
Joint project with . This link opens in a new tab.

Substantiated information by:

Paula Aguilera Peiro

Published: 19 November 2024
Updated: 19 November 2024

The donations that can be done through this webpage are exclusively for the benefit of Hospital Clínic of Barcelona through Fundació Clínic per a la Recerca Biomèdica and not for BBVA Foundation, entity that collaborates with the project of PortalClínic.

Subscribe

Receive the latest updates related to this content.

Thank you for subscribing!

If this is the first time you subscribe you will receive a confirmation email, check your inbox

An error occurred and we were unable to send your data, please try again later.

Vitiligo related news